Open Access Highly Accessed Research article

A randomized, double-blind, placebo-controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced non-dialysis-dependent chronic kidney disease

Wajeh Qunibi1*, Wolfgang C Winkelmayer2, Richard Solomon3, Moustafa Moustafa4, Paul Kessler5, Chiang-Hong Ho6, Jonathan Greenberg7 and Jose A Diaz-Buxo6

Author Affiliations

1 Department of Medicine, University of Texas Health Sciences Center, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA

2 Division of Nephrology, Department of Medicine, Stanford University School of Medicine, 780 Welch Road, Suite 106, Palo Alto, CA 94304, USA

3 Department of Medicine, 2308 Rehab 2, UHC Campus Fletcher Allen Health Care, University of Vermont, Burlington, VT, 05401, US

4 South Carolina Nephrology and Hypertension, 1184 Orangeburg Mall Circle, Orangeburg, SC 29115-3439, USA

5 Clinical, Medical and Regulatory Affairs, Nabi Biopharmaceuticals, 12276 Wilkins Avenue, Rockville, MD, 20852, USA

6 Renal Therapies Group, Fresenius Medical Care, 309 East Morehead Street, Suite 285, Charlotte, NC, 28202, USA

7 Daiichi Sanky, 399 Thornall Street, Edison, New Jersey 08837, USA

For all author emails, please log on.

BMC Nephrology 2011, 12:9  doi:10.1186/1471-2369-12-9

Published: 16 February 2011

Additional files

Additional file 1:

A. Sample size calculation in the original study protocol. File contains calculation of the sample size. B. Adverse Events (AE) in the calcium acetate and placebo groups. File contains all adverse events in the study subjects.

Format: DOCX Size: 22KB Download file

Open Data